We recently published a list of 11 Best Breakout Stocks to Buy According to Analysts. In this article, we are going to take a ...

A new drug application seeking the approval of ziftomenib was submitted to the FDA on April 8, 2025. This indication is for ...

InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that its new generation pan-TRK inhibitor zurletrectinib ...

Here is a recap of every FDA approval announced by the regulatory agency in the month of April, spanning various cancer types ...

The FDA has approved a ready-to-dilute, multi-dose formulation of thiotepa (Tepylute) for use in breast and ovarian ...

Motorola Edge 60 Fusion Review: The Edge 60 Fusion is Motorola’s first phone launch of 2025. The successor to last year’s Edge 50 Fusion (review), which was one of the highest-selling Edge ...

Zai Lab Limited (NASDAQ: ZLAB) shares barely moved Monday, on word China’s National Medical Products Administration (NMPA) has accepted the supplemental New Drug Application (sNDA) for repotrectinib ...

Zai Lab's repotrectinib label expansion accepted in China for treating advanced solid tumors with NTRK gene fusion.

In February 2025, China's NMPA granted priority review to repotrectinib for the treatment of adult patients with advanced solid tumors that have an NTRK gene fusion. In June 2024, AUGTYRO ...

for repotrectinib for the treatment of adult patients with solid tumors that harbor a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. The application is intended for patients whose ...